Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03814187 · ClinicalTrials.gov registry record · Phase 3
Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,275
- Enrollment target
NCT03814187 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 3,275 participants.
The verdict
NCT03814187, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,275 participants
- Enrollment target
Study Summary
The purpose of this extension study was to evaluate the efficacy, safety, and tolerability of long-term dosing of Inclisiran. The study was a global multicenter study.
Interventions
- DRUG Inclisiran Sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,275 participants |
| Start Date | 2019-04-16 |
| Est. Completion | 2023-02-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03814187
The ClinicalTrials.gov registry entry for NCT03814187 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 3,275 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Inclisiran Sodium is the first listed.
NCT03814187 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03814187 about?
NCT03814187 is a clinical study titled "Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C". The purpose of this extension study was to evaluate the efficacy, safety, and tolerability of long-term dosing of Inclisiran. The study was a global multicenter study.
What is the current status of trial NCT03814187?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,275 participants. The study started on 2019-04-16. Estimated completion is 2023-02-13.
What interventions are being tested in trial NCT03814187?
The interventions under investigation include: Inclisiran Sodium (DRUG).
Who is sponsoring clinical trial NCT03814187?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.